Q4 $800M / FY $3,356MAdj. Revenue(1): Q4 $800M / FY $3,176MPre-tax Income (Loss): Q4 $(82)M / FY $504MAdj. EBITDA Margin(1): ...

Second Quarter Fiscal 2025 Financial Summary Additional Financial Highlight Financial Highlights ($, in millions, except per share data) Income Statement Items ... expense and the tax effects of these ...

BURLINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global industry leader in AI for transportation, today reported its first quarter fiscal year 2025 ...

June 23, 2021, Paper: "I provide fact-checking on some of the year’s most important headlines regarding the gendered impact of the pandemic, in particular the “she-cession,” hours of childcare, ...

Picking the right financial advisor is one of the most important life choices you can make. A good advisor can not only help boost the returns on your investment portfolio but also provide you with ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter. In addition to ...

The Financial Times reported on Tuesday that Brussels ... A Commission spokesperson told reporters it was assessing rather than reviewing its cases, which was not linked to Trump's arrival ...

analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter. Analysts may ...

These financial adjustments and projections highlight a positive outlook for BridgeBio Pharma, justifying the high expected share price return of 52.8%, which supports the Buy recommendation.